drugset / Trial / NCT04664972
Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC
RandomizedParallel-groupOpen-labelTreatment
Summary
Previous studies have shown that TNBC is sensitive to DNA crosslinking-related chemotherapeutic drugs such as platinum. However, there is a lack of large sample prospective clinical data to compare the efficacy of TP and EC-T / TEC regimen in the neoadjuvant chemotherapy of TNBC. Besides, the application of anthracycline drugs is limited to a certain extent due to the cardiotoxicity. Based on the above evidence, the researchers hope to explore a more effective and safer new adjuvant therapy for TNBC.
Timeline
- Start
- 2018-11-23
- Primary completion
- 2022-11-26
- Completion
- 2022-11-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Comparator | Cyclophosphamide | Other / unclassified | 500 mg/m2 | — |
| Comparator | Doxorubicin | Other / unclassified | 50 mg/m2 | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | — |